{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:25:59Z","timestamp":1790400359970,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jaad.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jaad.2017.07.013","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T11:30:14Z","timestamp":1504870214000},"page":"845-854.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry"],"prefix":"10.1016","volume":"77","author":[{"given":"David","family":"Fiorentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Langholff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fakharzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2017.07.013_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.013_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546630701364768","article-title":"Psoriasis comorbidities","volume":"19","author":"Gottlieb","year":"2008","journal-title":"J Derm Treat"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.013_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.013_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the Health Improvement Network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2017.07.013_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2017.07.013_bib6","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.013_bib7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2017.07.013_bib8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.07.013_bib9","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.07.013_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The risk of melanoma and hematologic cancers in patients with psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.07.013_bib11","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2012","journal-title":"J Am Acad Derm"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.013_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.013_bib13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bjd.12404","article-title":"Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)","volume":"168","author":"Reich","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.013_bib14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.013_bib15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"19","key":"10.1016\/j.jaad.2017.07.013_bib16","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systemic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.013_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis\u00a0factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.013_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.013_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.013_bib20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.013_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.013_bib22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2017.07.013_bib23","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.013_bib24","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.013_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jdv.12492","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry","volume":"29","author":"Carretero","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2017.07.013_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"10.1016\/j.jaad.2017.07.013_bib27","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.013_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.13013","article-title":"Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.013_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","article-title":"Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.013_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.07.013_bib31","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Available at: www.seer.cancer.gov. Accessed January 27, 2017."},{"issue":"9","key":"10.1016\/j.jaad.2017.07.013_bib32","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1592\/phco.24.13.1105.38083","article-title":"Pharmacoepidemiology II: the nested case-control study\u2014a novel approach in pharmacoepidemiological research","volume":"24","author":"Etminan","year":"2004","journal-title":"Pharmacotherapy"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217321151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217321151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T17:26:01Z","timestamp":1535390761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217321151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0190962217321151"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.013","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}